Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer

JCO Precis Oncol. 2021 Jan 8:5:PO.20.00183. doi: 10.1200/PO.20.00183. eCollection 2021.

Swapnil Parmar¹, Jamie M Keck^{1

2}, Ben Kong¹, Regan Look³, Brett Johnson^{1

2

4}, Janice Patterson¹, Marilyne Labrie^{1

5}, Alexander R Guimaraes^{1

5

6}, Christopher L Corless^{1

7}, Carol Beadling¹, Annette Kolodzie^{1

2}, Raymond Bergan¹, Joe W Gray^{1

2

4}, Gordon B Mills^{1

5

8}, Zahi I Mitri¹

¹ Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
² Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, OR.
³ Compass Oncology, Portland, OR.
⁴ Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR.
⁵ Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR.
⁶ Department of Diagnostic Radiology, Oregon Health and Science University, Portland, OR.
⁷ Department of Pathology, Oregon Health and Science University, Portland, OR.
⁸ Department of Systems Biology, the University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Publication types